Skip to content
Screener

Accounts Receivable at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$15.69M+563%
Gilead Sciences logo
Gilead SciencesGILD
$5.9B+5.0%
ALN
Alnylam PharmaceuticalsALNY
$912.74M+60.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$25.75M+44.0%
Assembly Biosciences logo
Assembly BiosciencesASMB
$451K
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$38.42M-45.1%

Segments

By product

See full
Revenue from collaborations and licenses$178.7M

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$914.6M+42.4%
Enterprise value$891.52M+47.1%
P/E5.7×
P/S4.8×-36.9×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:AccountsAndOtherReceivablesNetCurrent.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 7:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001447028-26-000021
Line itemMarch 31, 2026December 31, 2025
Cash and cash equivalents$23,706$18,008
Investments in marketable securities, current71,52073,463
Accounts receivable1,3121,447
License receivable from Genevant178,741
Prepaid expenses and other current assets1,7321,538
Total current assets277,01194,456
Property and equipment, net of accumulated depreciation and impairment of $224 (December 31, 2025: $213)2232
Other non-current assets131130

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Arbutus Biopharma Corporation's accounts receivable?
Arbutus Biopharma Corporation (ABUS) reported accounts receivable of $178.74M in Q1 2026.
How has Arbutus Biopharma Corporation's accounts receivable changed year-over-year?
Arbutus Biopharma Corporation's accounts receivable increased by 15021.9% year-over-year, from $1.18M to $178.74M.
What is the long-term trend for Arbutus Biopharma Corporation's accounts receivable?
Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's accounts receivable has grown at a -100.0% compound annual growth rate (CAGR), from $1.31M to $0.
What does accounts receivable mean?
Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.

Ask your AI about Arbutus Biopharma Corporation's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude